Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Thiogenesis Therapeutics Corp
V.TTI
Alternate Symbol(s):
TTIPF
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a...
thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the obstacles facing thiol-based drugs, their short half-life, gastrointestinal (GI) side effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for MELAS, Leigh syndrome, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:TTI)
New Post
View:
Posts & Comments
Threaded Posts
(91)
•••
MarketMakerss
X
Post by
MarketMakerss
on Dec 02, 2024 4:00pm
TTI Attains DTC Eligibility in the US
Last week, clinical-stage biotech company Thiogenesis Therapeutics (TTI.v) announced attaining DTC eligibility in the US, facilitating electronic settlement of its common shares; a significant
...more
(91)
•••
MarketMakerss
X
Post by
MarketMakerss
on Nov 21, 2024 6:31pm
TTI's Substantial Addressable Market
Targeting pediatric diseases with unmet medical needs and zero approved drugs or treatments, Thiogenesis Therapeutics (TTI.v) is a biopharmaceutical company focused on developing novel thiol-based
...more
(91)
•••
MarketMakerss
X
Post by
MarketMakerss
on Nov 11, 2024 7:19pm
TTI's Important Core Patent Allowed in Europe
Important Core Patent Allowed In Europe - Thiogenesis Therapeutics (TTI.v) Announced European Approval Last week, Thiogenesis Therapeutics (TTI.v) announced the approval of its European
...more
(12)
•••
Bassenon123
X
Comment by
Bassenon123
on Apr 22, 2022 3:36am
RE:RE:RE:RE:listing today
H1..
(5)
•••
GoodAtCharts
X
Comment by
GoodAtCharts
on Apr 20, 2022 11:19am
RE:RE:RE:listing today
Complete in H1 or Q1?
(12)
•••
Bassenon123
X
Comment by
Bassenon123
on Apr 20, 2022 4:13am
RE:RE:listing today
Waiting to hear the results of the PK study in Australia (dosage in 12 volunteers) which is expected to complete in H1 2022
(5)
•••
GoodAtCharts
X
Comment by
GoodAtCharts
on Apr 19, 2022 12:31pm
RE:listing today
I have some shares of this company any thoughts? Target prices?
(12)
•••
Bassenon123
X
Post by
Bassenon123
on Apr 13, 2022 4:43am
listing today
finally....live today...if all goes well
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
Are PGM mining stocks an attractive area for your next portfolio allocation?
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth